This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 'Mad Money' Recap: Buying Retail (Correct)

Lightning Round

In the Lightning Round, Cramer was bullish on Stratasys (SSYS), Intersil (ISIL), Exelixis (EXEL), Lowe's (LOW) and Walt Disney (DIS).

Cramer was bearish on Voxeljet AG (VJET), LSI Corp (LSI) and Sangamo Biosciences (SGMO).

Executive Decision: Mark Ahn

For his second "Executive Decision" segment, Cramer spoke with Dr. Mark Ahn, president and CEO of Galena Biopharma (GALE), a smaller, speculative biotech company that's showing a lot of promise with its NeuVax anti-cancer treatment currently in Phase III testing. Shares of Galana are up over 233% since November.

Ahn said Galena has seen exciting and promising results from its studies so far, which have shown either a delay or prevention of cancer recurrence. He said the company has a multi-billion dollar opportunity in front of it, both for breast cancer as well as gastric cancer and as a standalone and combination treatment with other drugs.

Must Read: Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

When asked about delays in getting the Phase III stuff off the ground, Ahn said it takes time to set up the 130 hospitals in 15 countries that will be testing the drug, but the study will be fully enrolled by mid-year.

Ahn also responded to critics' charge Galena is ignoring the fact that NeuVax may not help, and may even harm, some patients. He said that it's totally appropriate for any new drug to have its skeptics, and NeuVax, like every drug, has a segment of patients for which it's most effective and others where it's not effective. In Phase II testing, he continued, NeuVax saw 0% cancer recurrence and that's what it is now testing in Phase III.

Cramer said there is a lot of research, both pro and con, regarding Galena and investors need to do their homework and be informed.

No Huddle Offense

In his "No Huddle Offense" segment, Cramer opined on the skepticism and resistance surrounding his recommendation of Bank of America (BAC - Get Report), a holding in his charitable trust, Action Alerts PLUS.

Cramer said that there's no denying that Bank of America is a hated story for many, but no one could have handled the disaster that was the Countrywide acquisition. As the bank recovers, yes, it doesn't yet pay a dividend, but that decision it up to regulators, not the bank.

Some skeptics call for a breakup of Bank of America, but Cramer said that the bank is in good shape with its current structure. Still others cite the ailing mortgage market as another reason to avoid the stock. But Cramer said mortgages are a commodity and rising net interest margins are what matters most.

All in all, Cramer said these negatives just don't hold water, and there's a lot to like about this most-hated of banks.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC

At the time of publication, Cramer's Action Alerts PLUS had a position in BAC.

Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for, Inc., and CNBC, and a director and co-founder of All opinions expressed by Mr. Cramer on "Mad Money" are his own and do not reflect the opinions of or its affiliates, or CNBC, NBC Universal or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or is related to the specific opinions expressed by him on "Mad Money."

None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. When that is the case, appropriate disclosure is made on the program and in the "Mad Money" recap available on The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions, and must hold all securities in the Action Alerts PLUS Portfolio for at least one month, and is not permitted to buy or sell any security he has spoken about on television or on his radio program for five days following the broadcast.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BAC $12.28 -5.10%
GALE $0.66 4.10%
LOCK $11.63 -0.51%
AAPL $94.37 0.37%
FB $100.00 -3.90%


Chart of I:DJI
DOW 15,901.65 -303.32 -1.87%
S&P 500 1,846.72 -33.33 -1.77%
NASDAQ 4,272.86 -90.2840 -2.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs